​Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics

Shanghai Bao Pharmaceutical Co., Ltd. (“Bao Pharma”, stock code: 02659.HK) was officially listed today on the Main Board of the Hong Kong Stock Exchange, marking a new phase in the company’s development as it steps onto the international capital market. The management team and distinguished guests attended the ceremony, witnessing this moment.

Reshaping Biopharmaceuticals and Opening a New Track for Domestic Innovative Protein Drugs

Founded in 2019, Bao Pharma has developed a new generation of innovative protein therapeutics aimed at life-threatening diseases with high unmet clinical needs. Bao Pharma now has 12 pipelines commercialized, in clinical or pre-clinical development spanning multiple therapeutic areas. Three core products—KJ103, KJ017 and SJ02—have each achieved breakthroughs in acute autoimmune diseases, high-volume subcutaneous drug delivery, and assisted reproduction, respectively.

· KJ103: The world’s first low pre-existing neutralizing antibody IgG-degrading enzyme entering Ph3, with potential for repeat dosing and functional cure across various IgG-mediated autoimmune conditions, such as kidney-transplant desensitization, anti-GBM disease, and Guillain–Barré syndrome (GBS).

· KJ017: China’s first recombinant human hyaluronidase submitted for NDA; designed for high-volume subcutaneous administration of antibodies, antibiotics, and other therapeutics in broad collaboration with domestic and international partners.

· SJ02: China’s first approved long-acting follicle-stimulating hormone (FSH), aiming to reduce injection frequency while enhancing safety and patient compliance.

Innovation-Driven, Value-Oriented: Building a Sustainable Biologics Ecosystem

Bao Pharma has established a reliable and scalable recombinant biologics manufacturing network capable of supplying medicines efficiently, stably, and with full quality control.
On this foundation, Bao Pharma continues to expand its innovation pipeline, launching a range of next-generation protein therapeutics designed to address unmet clinical needs. It has also established long-term strategic partnerships with multiple collaborators to jointly explore the clinical and commercial potential of novel therapies. With end-to-end capabilities from R&D to manufacturing and supply, Bao Pharma is driving China’s recombinant biologics from “manufacturable” to “sustainably innovative”, delivering enduring momentum for industry growth. According to Frost & Sullivan projections, Bao Pharma’s clinically addressable market in China is expected to exceed RMB 50 billion by 2033.

About Shanghai Bao Pharmaceutical

Founded in 2019, Shanghai Bao Pharmaceutical Co., Ltd. is an innovative biotechnology company specializing in clinical development, synthetic biology and recombinant biologics. The company focuses on replacing traditional biochemically extracted products and upgrading validated therapies, building a diversified pipeline across high-volume subcutaneous drug delivery, autoimmune diseases and assisted reproduction. With leading chassis-cell engineering capabilities, a stable commercial manufacturing system, and an international R&D team, Bao Pharma aims to become a global frontrunner in recombinant biologics.

Forward-Looking Statement

This press release may contain forward-looking statements based on current expectations, assumptions, and projections made by the management of Shanghai Bao Pharmaceutical Co., Ltd. (“Bao Pharma”). These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such statements include, but are not limited to, descriptions of business strategies, future operational plans, R&D progress, clinical-trial outcomes, commercial prospects, and financial performance. Except as required by law or regulation, Bao Pharma undertakes no obligation to update or revise any forward-looking statement to reflect new information, future events, or other changes. This press release is for informational purposes only and does not constitute investment advice or an offer to purchase securities of the company.